Further, ALT is commonly used as an inclusion criterion in NAFLD clinical trials, and ALT > 250 U/L is frequently an exclusion criterion due to insufficient data on children with levels > 250 U/L. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.